示例按钮
HOME
ABOUT
TECHNOLOGY
R & D
Pipeline
rhTSH
Molecular Nuclear Imaging
PD-L1 Expression
TIL Distribution
NEWS
CONTACT
中文
Home
Close
Back
OUR MISSION
+ 查看更多
We are dedicated to transforming
the diagnosis and treatment of cancer by
developing innovative, game-changing
radiopharmaceuticals.
NEWS
+ 查看更多
SmartNuclide Biopharma Announces First Patient Treated in Phase 1/2 Clinical Trial of SNA001 for Well-Differentiated Thyroid Cancer
2019-02-12
SmartNuclide’s SNA001 Receives NMPA’s First Investigational New Drug Approval for Recombinant Human TSH
2018-10-18
Innovative Radiopharmaceutical Company SmartNuclide Closes Series Pre-A Financing
2018-03-07
COPYRIGHT © 2019 SMARTNUCLIDE